Madrigal Pharmaceuticals (MDGL) Short term Debt (2010 - 2016)

Madrigal Pharmaceuticals (MDGL) has 7 years of Short term Debt data on file, last reported at $10000.0 in Q2 2016.

• Short term Debt for Q2 2016 came in at $10000.0, down 99.89% year-over-year; the trailing twelve-month figure through Jun 2016 was $10000.0 (down 99.89% YoY), and the FY2015 annual result was $4.6 million, down 50.0% from the prior year.
• Short term Debt slipped to $10000.0 in Q2 2016 per MDGL's latest filing, from $2.3 million in the prior quarter.
• Over five years, Short term Debt peaked at $9.5 million in Q4 2013 and troughed at $10000.0 in Q2 2016.
• A 5-year average of $6.9 million and a median of $7.9 million in 2012 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2014 and 2016: Short term Debt jumped 200.58% in 2014, then sank 99.89% in 2016.
• A 5-year view of Short term Debt shows it stood at $7.9 million in 2012, then advanced by 19.27% to $9.5 million in 2013, then declined by 2.51% to $9.2 million in 2014, then sank by 50.0% to $4.6 million in 2015, then sank by 99.78% to $10000.0 in 2016.
• Business Quant data shows MDGL's Short term Debt at $10000.0 in Q2 2016, $2.3 million in Q1 2016, and $4.6 million in Q4 2015.